Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
75 hedge funds and large institutions have $118M invested in Agile Therapeutics in 2020 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 27 reducing their positions, and 14 closing their positions.
275% more call options, than puts
Call options by funds: $1.46M | Put options by funds: $388K
10% more capital invested
Capital invested by funds: $107M → $118M (+$11.1M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 79 → 75 (-4)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
30% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$2.37M |
| 2 |
DCM
DG Capital Management
New York
|
+$837K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$653K |
| 4 |
Two Sigma Advisers
New York
|
+$246K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$241K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.74M |
| 2 |
Renaissance Technologies
New York
|
-$401K |
| 3 |
Jane Street
New York
|
-$302K |
| 4 |
SG Americas Securities
New York
|
-$298K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$281K |
AGRX Hedge Fund Activity: Q3 2020 in Review
75 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q3 2020, worth a combined $118M — up 10% from $107M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of AGRX and 10 opened new positions — a net loss of 4 holders — while 27 trimmed existing stakes and 19 added.
The largest buyer was Manulife (Manufacturers Life Insurance), adding an estimated $2.37M. The largest seller was Millennium Management, exiting entirely with an estimated $1.74M sold.
- 75 institutional investors held Agile Therapeutics (AGRX) as of Q3 2020, down from 79 in Q2 2020.
- Funds reported $118M of Agile Therapeutics stock for Q3 2020, up 10% quarter-over-quarter.
- 10 funds opened new Agile Therapeutics positions in Q3 2020 and 14 closed out, a net change of -4 holders.
- The largest Agile Therapeutics buyer in Q3 2020 was Manulife (Manufacturers Life Insurance), an estimated $2.37M added.
- The largest Agile Therapeutics seller in Q3 2020 was Millennium Management, an estimated $1.74M sold.
Based on aggregated 13F filings for Q3 2020.